Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 8, 2011, Pages 1475-1482

  Masola, Valentina ^a   Gambaro, Giovanni ^c   Tibaldi, Elena ^a   Onisto, Maurizio ^a   Abaterusso, Cataldo ^b   Lupo, Antonio ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

AGE; Albuminuria; Diabetic nephropathy; Heparanase; PI3K AKT; Syndecan 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; GLUCOSE; HEPARAN SULFATE; HEPARANASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SYNDECAN 1;

ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY PROXIMAL TUBULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ALBUMINS; BASE SEQUENCE; CELL LINE; DIABETIC NEPHROPATHIES; GLUCOSE; GLUCURONIDASE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEK293 CELLS; HEPARITIN SULFATE; HOMEOSTASIS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES, PROXIMAL; RNA, MESSENGER; RNA, SMALL INTERFERING; SERUM ALBUMIN; SERUM ALBUMIN, BOVINE; SYNDECAN-1; TRANSCRIPTIONAL ACTIVATION;

EID: 79959358165     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.05.004     Document Type: Article

References (28)

1. Gilbertson D.T., Liu J., Xue J.L., Louis T.A., Solid C.A., Ebben J.P., Collins A.J. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J. Am. Soc. Nephrol. 2005, 16:3736-3741.
2. Gilbert R.E., Cooper M.E. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?. Kidney Int. 1999, 56:1627-1637.
3. Bohle A., Wehrmann M., Bogenschutz O., Batz C., Muller C.A., Muller G.A. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol. Res. Pract. 1991, 187:251-259.
4. Mauer S.M., Steffes M.W., Ellis E.N., Sutherland D.E., Brown D.M., Goetz F.C. Structural-functional relationships in diabetic nephropathy. J. Clin. Invest. 1984, 74:1143-1155.
5. Pollock C.A., Poronnik P. Albumin transport and processing by the proximal tubule: physiology and pathophysiology. Curr. Opin. Nephrol. Hypertens. 2007, 16:359-364.
6. Gekle M. Renal tubule albumin transport. Annu. Rev. Physiol. 2005, 67:573-594.
7. Caruso-Neves C., Pinheiro A.A., Cai H., Souza-Menezes J., Guggino W.B. PKB and megalin determine the survival or death of renal proximal tubule cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18810-18815.
8. van den Hoven M.J., Rops A.L., Vlodavsky I., Levidiotis V., Berden J.H., van der Vlag J. Heparanase in glomerular diseases. Kidney Int. 2007, 72:543-548.
9. Vlodavsky I., Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 2001, 108:341-347.
10. Masola V., Maran C., Tassone E., Zin A., Rosolen A., Onisto M. Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer 2009, 9:304.
11. Ilan N., Elkin M., Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol. 2006, 38:2018-2039.
12. van den Hoven M.J., Rops A.L., Bakker M.A., Aten J., Rutjes N., Roestenberg P., Goldschmeding R., Zcharia E., Vlodavsky I., van der Vlag J., Berden J.H. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 2006, 70:2100-2108.
13. Kure S., Yoshie O. A syngeneic monoclonal antibody to murine Meth-A sarcoma (HepSS-1) recognizes heparan sulfate glycosaminoglycan (HS-GAG): cell density and transformation dependent alteration in cell surface HS-GAG defined by HepSS-1. J. Immunol. 1986, 137:3900-3908.
14. Gattei V., Godeas C., Degan M., Rossi F.M., Aldinucci D., Pinto A. Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. Br. J. Haematol. 1999, 104:152-162.
15. Xu X., Rao G., Maxhimer J.B., Prinz R.A., Lewis E.J. Mechanism of action of sulodexide-mediated control of proteinuria: inhibition of heparanase-1 activity [abstract]. J. Am. Soc. Nephrol. 2005, 16:673A.
16. Phillips A.O. The role of renal proximal tubular cells in diabetic nephropathy. Curr. Diab. Rep. 2003, 3:491-496.
17. Coward R.J., Welsh G.I., Yang J., Tasman C., Lennon R., Koziell A., Satchell S., Holman G.D., Kerjaschki D., Tavare J.M., Mathieson P.W., Saleem M.A. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005, 54:3095-3102.
18. Neumiller J.J., White J.R., Campbell R.K. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010, 70:377-385.
19. Xu D., Kyriakis J.M. Phosphatidylinositol 3?-kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by advanced glycation end products. J. Biol. Chem. 2003, 278:39349-39355.
20. Singh B.K., Mascarenhas D.D. Bioactive peptides control receptor for advanced glycated end product-induced elevation of kidney insulin receptor substrate 2 and reduce albuminuria in diabetic mice. Am. J. Nephrol. 2008, 28:890-899.
21. Ma J., Liu T., Dong X. Advanced glycation end products of bovine serum albumin-induced endothelial-to-mesenchymal transition in cultured human and monkey endothelial cells via protein kinase B signaling cascades. Mol. Vis. 2010, 16:2669-2679.
22. Ilan N., Elkin M., Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol. 2006, 38:2018-2039.
23. An X.F., Zhou L., Jiang P.J., Yan M., Huang Y.J., Zhang S.N., Niu Y.F., Ten S.C., Yu J.Y. Advanced glycation end-products induce heparanase expression in endothelial cells by the receptor for advanced glycation end products and through activation of the FOXO4 transcription factor. Mol. Cell. Biochem. 2011, 10.1007/s11010-011-0804-7.
24. Wijnhoven T.J., Lensen J.F., Rops A.L., McCarthy K.J., van der Vlag J., Berden J.H., van den Heuvel L.P., Kuppevelt T.H. Anti-proteinuric effects of glycosaminoglycan-based drugs. Curr. Opin. Mol. Ther. 2007, 9:364-377.
25. Gambaro G., Kinalska I., Oksa A., Pont'uch P., Hertlova M., Olsovsky J., Manitius J., Fedele D., Czekalski S., Perusicova J., Skrha J., Taton J., Grzeszczak W., Crepaldi G. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J. Am. Soc. Nephrol. 2002, 13:1615-1625.
26. Yang Y., MacLeod V., Dai Y., Khotskaya-Sample Y., Shriver Z., Venkataraman G., Sasisekharan R., Naggi A., Torri G., Casu B., Vlodavsky I., Suva L.J., Epstein J., Yaccoby S., Shaughnessy J.D., Barlogie B., Sanderson R.D. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007, 110:2041-2048.
27. Chen L., Sanderson R.D. Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One 2009, 4:e4947.
28. Mahtouk K., Hose D., Raynaud P., Hundemer M., Jourdan M., Jourdan E., Pantesco V., Baudard M., De Vos J., Larroque M., Moehler T., Rossi J.F., Reme T., Goldschmidt H., Klein B. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007, 109:4914-4923.